Paul A. Dickinson

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Pasi A. Jänne, James Chih‐Hsin Yang, Dong‐Wan Kim et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

David Planchard, Kathryn H. Brown, Dong‐Wan Kim et al. · Cancer Chemotherapy and Pharmacology · 2016 · 142 citations

Therapeutic Drug Monitoring, Healthy Volunteers, Pharmacology +7

Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor

Paul A. Dickinson, Mireille Cantarini, J. Collier et al. · Drug Metabolism and Disposition · 2016 · 128 citations

An Investigation into the Utility of a Multi-compartmental, Dynamic, System of the Upper Gastrointestinal Tract to Support Formulation Development and Establish Bioequivalence of Poorly Soluble Drugs

Paul A. Dickinson, Ragheb Abu Rmaileh, L. J. Ashworth et al. · The AAPS Journal · 2012 · 105 citations · Full text

Support Formulation Development, Upper Gastrointestinal Tract, Physiology +7

Oral bioavailability of cinnarizine in dogs: Relation to SNEDDS droplet size, drug solubility and in vitro precipitation

Anne Larsen, Anja G. Ohlsson, Britta Polentarutti et al. · European Journal of Pharmaceutical Sciences · 2012 · 97 citations

Pharmaceutical Science, Oral Bioavailability, Medicine +5